Drugs
Brensocatib: First Approval.
Susan J Keam
Published: 202510.1007/s40265-025-02255-0
Abstract
Brensocatib (BRINSUPRI™), an oral, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), is being developed by Insmed Incorporated under license from AstraZeneca for the treatment of neutrophil-mediated diseases, including non-cystic…
Preview only. Read the full abstract at the source